Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year High – Here’s What Happened

Cardiol Therapeutics Inc. (TSE:CRDL) reached a new 52-week high on Wednesday . The company traded as high as C$3.23 and last traded at C$3.19, with a volume of 299583 shares traded. The stock had previously closed at C$3.06.

Cardiol Therapeutics Trading Down 12.3%

The company has a debt-to-equity ratio of 0.45, a current ratio of 5.55 and a quick ratio of 6.84. The company has a fifty day moving average of C$2.17 and a 200-day moving average of C$1.84. The firm has a market capitalization of C$323.60 million, a PE ratio of -8.15 and a beta of 0.58.

Cardiol Therapeutics (TSE:CRDL) last issued its earnings results on Wednesday, August 12th. The company reported C($0.05) EPS for the quarter. On average, sell-side analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.